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Problem Identification and Description 
of Need
 Acute hepatitis C infection is on the rise in the United States. Acute HCV infection increased 
more than 2-fold (0.3 to 0.7 cases/100 000) from 2004 to 2014 (1) 
 National increase in hepatitis C infection has mirrored increases in injection drug use
 The largest increases in acute HCV infections were among persons aged 18 to 29 and 30 to 39 
years, 400% and 325% respectively. In person aged 18 to 29 there was an 817%  increase in 
admissions for injection of prescription opioids; and 600% increase in admissions for heroin 
injection. In persons age 30 to 39 year there was a 169% increase in admissions for injection of 
prescription opioids; and 77% increase in admissions for heroin injection (1)
 New HCV infections have disproportionally effected younger populations who are more likely to 
suffer from opioid use disorder. 
 One meta analysis estimated that in developed nations the prevalence rate of HCV in 
individuals with one year of injection drug use is 32% and 53% at five years (2)
 Newly reported HCV cases in Vermont is on the rise. 541 new infections reported in 2010 and 
907 in 2014. The newly reported HCV case rate per 1,000 individuals increased from .69 to 
1.42 in Franklin County (3)
Public Health Cost
 The rate of death related to HCV per 100,000 population was 4.13 in 2017 (4)
 Healthcare costs attributed to HCV infection per year have been estimated to 
range from $10,561 for noncirrhotic disabled adults to $46,263 for 
nondisabled adults with end-stage liver disease (5)
 The first full year (2014) following the approval of interferon-free treatment, 
an estimated 12,175 adults with HCV were cured in Medicaid nationwide. 
Each avoided an estimated $15,907/year in healthcare costs associated with 
HCV (5)
 Getting high risk patients screened and treated for HCV reduces health care 
costs. By 2022, the recurrent annual avoidance of healthcare costs related to 
HCV treatment is estimated at $12 billion in total cumulative savings to 
Medicaid (5)
Community Perspective
 Barbara Wynes, MAT RN Care Coordinator
“It is important for patients starting MAT for opioid use disorder to be screened for HCV because many of the 
MAT patients are former intravenous drug uses. Screening can be challenging because some patients do not want 
to give blood samples for screening because they are needle phobic or find needles triggering.”  
 Stefanie Comstock, MAT Care Coordinator
“I think that some patients have not been screened because of fear and shame related to their addiction... I am 
not sure if people are aware of the new hepatitis C medications that have fewer side effects compared to the 
older hepatitis C medications.”
Summary of interviews:
Patients in MAT clinic are at high risk for previous HCV infection
It has been challenging to get patients screened for HCV
Some patients have poor knowledge surrounding HCV
Many patients are unaware of new treatments that are available
Intervention and Methodology
 As patients were seen in the clinic for medication-assisted treatment of 
opioid used disorder their charts were reviewed to determine if they had 
been screened for HCV. Their screening status was recorded
 Patients in the MAT clinic who did not have documented HCV status were 
asked if they were interested in receiving information regarding HCV. If a
patient expressed interest, information from the handout on the following 
slide was presented to them
 Patients who did not have a documented HCV status were encouraged and 
offered HCV screening
Hepatitis C. Get tested, get treated
What is hepatitis C? 
It is a virus that is found in the blood and can cause liver 
damage
What are the symptoms of hepatitis C?
Usually there are no symptoms early in the disease. When 
a patient does experience symptoms, they can 
experience fatigue, decreased appetite, nausea, muscle 
or joint aches and weight loss.
How is hepatitis C spread?
Sharing drug needles or sharing instruments to snort 
drugs                                         
Unsterile tattooing, acupuncture, or piercings
Sharing toothbrushes, razors, or other things that could 
have blood on them
Blood transfusion in the United States before 1992
Rarely through sexual contact 
It is NOT spread by shaking hands, touching, kissing, 
sharing food or drinks, using the bathroom, mosquitos, 
sneezing or coughing
Is there a test for hepatitis C?
Yes! A simple blood test can be performed to check if you have 
been exposed to the virus.
Can it be treated?
Yes! Most of the time Hepatitis C can be cured. Usually the virus 
is treated for 12 weeks with a medication that comes in pill form. 
What if hepatitis C is not treated?
If a person is infected for years and they do not receive treatment 
they can develop liver failure or liver cancer which can result in 
death
After treatment can I get hepatitis C again?
Yes, unfortunately even after being cured of hepatitis C you can 
be transmitted hepatitis C again.
How can hepatitis C infection be prevented?
Never share needles or instruments to snort drugs. Never share 
things that could have blood on them. Avoid unsterile tattooing, 
acupuncture or piercings. Avoid unprotected sex with a partner 
who is hepatitis C positive
Information adapted from uptodate.com: 
Patient education: Hepatitis C (The Basics)
Images from: 
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Results
 Over the course of 8 days in clinic 36 patients’ charts were reviewed for HCV status 
 22 patients were identified who had been screened for HCV. 19 of these patients had negative tests. 2 
had spontaneously cleared infections. 1 had active infection.
 14 patients were identified who did not have documented HCV status. Education regarding HCV was 
provided to these patients. These patients were encouraged to have HCV testing and offered HCV 
testing. 
 Many patients who did not have HCV status documented reported that they thought that they had 
previously been tested by a former PCP or as part of a drug rehab program and did not think that HCV 
testing was necessary. A smaller number of patients reported that they were needle phobic and did 
not want to give blood for the test. One patient reported that screening had been attempted but 
venipuncture was unsuccessful previously in clinic. 
 Patients were surprised by some of the information about HCV that was presented to them. Many were 
surprised that HCV infection often does not have any symptoms. Others expressed surprise that HCV 
can be transmitted by routes other than IVDU, particularly that it can be transmitted by sharing 
instruments used in nasal insufflation of drugs
Effectiveness and Limitations
 Effectiveness
 This project was effective at recording screening rates of HCV in a MAT clinic in northern 
Vermont
 Helped to identify an area for improvement in the MAT clinic. In the clinic HCV testing is 
typically done at the time of physical exam. Many MAT patients are resistant to having a 
physical exam done which means that some patients have not received HCV screening
 Provided education about HCV to patients at high risk for infection
 Limitations
 The run time of this project was short. Not every MAT patient’s chart in the clinic was 
reviewed for prior HCV screen and not every patient in the clinic was offered HCV 
education
 Some patients were not interested in receiving information/education regarding HCV
 It is unclear if the information found during this project is generalizable to other MAT 
clinics around the state or nation
Future Interventions
 Possible future work in this area could include:
 Ensuring that patients in MAT clinic have also been screened for other 
transmittable diseases such as HIV and hepatitis B that this patient population is at 
high risk for
 Follow up with patients who did not have a documented HCV screen and ensure 
that they receive appropriate screening
 Determining if HCV education has any impact on screening rates, rate of HCV 
infection or other patient behavior
 Continue to identify and address barriers related to HCV screening
 Explore the feasibility of HCV treatment in the primary care clinic to help reduce 
barriers to HCV treatment
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